The aim of the study was to investigate the possible effect of a single dose of ACTH4-10 (30 mg subcutaneously) on memory as measured with a test battery appropriate for the study of "consolidation". Twenty depressive inpatients participated in the intraindividual double-blind cross-over comparison between ACTH4-10 and placebo in connection with the second and third treatment in the ECT series. ACTH4-10 (or placebo) was administered subcutaneously 30 min after unilateral ECT. Memory functions were examined 90 min before and 150 min after the administration of the drug. A similar design was used in a study of 20 inpatients with neurotic depression not treated with ECT. The results of both studies give no evidence of a positive influence of a single dose of ACTH4-10 on consolidation of memory. Possible sources of error are discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1600-0447.1980.tb00630.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of Haloperidol in Companion Psittacine Birds: 19 Cases (2012-2022).
J Avian Med Surg
January 2025
Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA,
The antipsychotic medication haloperidol has been used for many years in avian medicine as a pharmacologic therapy for refractory feather destructive behavior in pet parrots. However, despite its common use, there are no published studies evaluating its efficacy and adverse effects in psittacine birds. The goal of this study was to report the signalment, clinical presentation, dosing regimen, response to therapy, and adverse effects of companion psittacine birds prescribed oral haloperidol therapy at a single veterinary referral hospital.
View Article and Find Full Text PDFA Randomized, Blinded, Vehicle-Controlled Dose-Ranging Study to Evaluate and Characterize Remdesivir Efficacy Against Ebola Virus in Rhesus Macaques.
Viruses
December 2024
Gilead Sciences, Inc., Foster City, CA 94404, USA.
Ebola virus (EBOV) causes severe disease in humans, with mortality as high as 90%. The small-molecule antiviral drug remdesivir (RDV) has demonstrated a survival benefit in EBOV-exposed rhesus macaques. Here, we characterize the efficacy of multiple intravenous RDV dosing regimens on survival of rhesus macaques 42 days after intramuscular EBOV exposure.
View Article and Find Full Text PDFThe Benefits of COVID-19 Vaccination for Pregnant Patients Hospitalized with Respiratory Symptoms: A Retrospective Cohort Study in South Brazil.
Vaccines (Basel)
December 2024
Division of Pediatric Infectious Diseases, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA.
Objectives: SARS-CoV-2 infection is a known risk factor for adverse health outcomes in pregnancy, affecting both maternal and neonatal health. Mounting evidence suggests that even a single dose of an approved COVID-19 vaccine protects against severe SARS-CoV-2 infection and is safe for both pregnant persons and neonates. Southern Brazil was heavily affected by the COVID-19 pandemic, and the protective effects of the vaccine on maternal and neonatal health are not well described.
View Article and Find Full Text PDFImpact of Repeated Variant Exposures on Cellular and Humoral Immunogenicity Induced by SARS-CoV-2 Vaccines.
Vaccines (Basel)
December 2024
Department of Microbiology, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
Background/objectives: The emergence of the Omicron variant has complicated COVID-19 control and prompted vaccine updates. Recent studies have shown that a fourth dose significantly protects against infection and severe disease, though long-term immunity data remain limited. This study aimed to assess Anti-S-RBD antibodies and interferon-γ levels in healthcare workers 12 months after receiving bivalent Original/Omicron BA.
View Article and Find Full Text PDFEvaluation of Safety, Immunogenicity and Cross-Reactive Immunity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, in Older Adults.
Vaccines (Basel)
December 2024
Osivax, 70 Rue Saint-Jean-de-Dieu, 69007 Lyon, France.
In a Phase 2a, double-blind, placebo-controlled study including healthy participants aged 18-55 years, OVX836, a nucleoprotein (NP)-based candidate vaccine, previously showed a good safety profile, a robust immune response (both humoral and cellular) and a preliminary signal of protection (VE = 84%) against PCR-confirmed symptomatic influenza after a single intramuscular dose of 180 µg, 300 µg or 480 µg. : Using the same methodology, we confirmed the good safety and strong immunogenicity of OVX836 at the same doses in older adults (≥65 years), a key target population for influenza vaccination. : Significant humoral (anti-NP IgG) and cellular (interferon gamma (IFNγ) spot-forming cells per million peripheral blood mononuclear cells and specific CD4 IFNγ T-cells) immune responses were observed at the three dose levels, without clear dose-response relationship.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!